PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2250 participants.

Also called NCT04889872

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 2,250 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04889872
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Canada, Japan, Netherlands, Switzerland (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04889872. Randomized; no masking; primary purpose treatment. Start 2021-10-12 (actual); primary completion 2029-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
Acronym
PROGRESS
Condition
Aortic Stenosis, Calcific
Condition
Aortic Valve Stenosis
Intervention (Device)
SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA
Lead sponsor
Edwards Lifesciences (class: industry)

Record details

Record id
cardio:ct-nct04889872
Content hash
b83d6e5bb1e6a284a6d93aacb00bc5938598800bb4fc21edf1c0ab395bc628b5